Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Equity Average (2019 - 2025)

BridgeBio Pharma's Equity Average history spans 7 years, with the latest figure at -$2.0 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 49.22% year-over-year to -$2.0 billion; the TTM value through Dec 2025 reached -$2.0 billion, down 49.22%, while the annual FY2025 figure was -$1.8 billion, 26.45% down from the prior year.
  • Equity Average for Q4 2025 was -$2.0 billion at BridgeBio Pharma, down from -$1.9 billion in the prior quarter.
  • Across five years, Equity Average topped out at -$141.6 million in Q1 2021 and bottomed at -$2.0 billion in Q4 2025.
  • The 5-year median for Equity Average is -$1.2 billion (2022), against an average of -$1.2 billion.
  • The largest annual shift saw Equity Average tumbled 598.6% in 2021 before it grew 17.33% in 2024.
  • A 5-year view of Equity Average shows it stood at -$802.9 million in 2021, then plummeted by 47.67% to -$1.2 billion in 2022, then dropped by 7.04% to -$1.3 billion in 2023, then decreased by 5.86% to -$1.3 billion in 2024, then plummeted by 49.22% to -$2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Equity Average are -$2.0 billion (Q4 2025), -$1.9 billion (Q3 2025), and -$1.7 billion (Q2 2025).